July 2, 2019 08:30 AM EDTUpdated July 3, 06:52 AM

Boehringer builds out NASH pipeline with up to $870M deal with South Korea's Yuhan

Natalie Grover

Reporter

Germany’s Boehringer Ingelheim is expanding its ambitions in NASH, the untreated fatty liver disease that has ravaged the developed world, creating a lucrative target that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer builds out NASH pipeline with up to $870M deal with South Korea's Yuhan

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Boehringer builds out NASH pipeline with up to $870M deal with South Ko­re­a's Yuhan

Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Boehringer builds out NASH pipeline with up to $870M deal with South Korea's Yuhan